Clinical trial NCT02605304: 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Official title: Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: HIV-1 Infection
Hepatitis C
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Sponsor class: NETWORK
Collaborators: name: National Institute of Allergy and Infectious Diseases (NIAID)
First posted: 2015-11-16
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir. However, in some instances, treatment with sofosbuvir-containing therapy does not work. It is not known if people respond to retreatment with sofosbuvir, after it did not work the first time. There is an important need to understand retreatment options in those instances. This clinical trial was done to study the response to two different regimens, ledipasvir/sofosbuvir and ledipasvir/sofosbuvir with ribavirin, and to see if they are safe and well-tolerated in HCV-infected persons whose previous treatment with sofosbuvir had failed.

Detailed description: There is a pressing need to understand appropriate retreatment options for HCV-infected patients who fail direct acting antiviral (DAA)-based regimens. To date, over 100,000 prescriptions have been written for SOF. Recent data indicate that SOF-based treatment defined as SOF/RBV, SOF/pegylated-interferon (PEG-IFN)/RBV or SOF/simeprevir (SIM) +/- RBV have led to treatment response of 70-92% in HCV genotype (GT) 1 patients, depending on the regimen used and presence of liver cirrhosis. Thus, there is a growing number of individuals who have failed SOF-based regimens and are in need of a retreatment strategy, the majority of which are anticipated to be HCV GT1, given the US distribution of genotypes. There are no data to inform retreatment strategies for HIV-infected individuals with SOF failure, who have traditionally represented a harder to treat group and are impacted by DAA-antiretroviral (ARV) interactions.

This was a phase II retreatment study of HCV GT1 and HIV coinfected participants who had previous HCV virologic failure on a SOF-based regimen. Participants were randomized to one of two treatment arms: 12 weeks of LDV/SOF with weight-based RBV (Arm A) or 24 weeks of LDV/SOF alone (Arm B). The targeted sample size was 40, 20 participants in each arm.

Post-entry, the study visits were scheduled at weeks 1, 2, 4, 8, 12, 16, 20 and 24 after study entry (with week 16, 20, 24 visits limited to those on the 24-week regimen), and at 4, 12 and 24 weeks after treatment discontinuation. The total study duration was 36 weeks in Arm A and 48 weeks in Arm B. At each visit, a physical examination and blood collection were conducted. HCV RNA was tested at each visit. For female participants of reproductive potential, pregnancy tests were done. At on-treatment visits, participants also completed an HCV treatment adherence questionnaire. Urinalysis was conducted at all on-treatment visits and at 4 weeks post treatment. At select visits, plasma, whole blood, urine and dried blood spots were collected.

The study was randomized because there was clinical equipoise on the benefits and drawbacks in the two study arms. The study was not designed to be powered for comparisons between the randomized study arms, and no formal statistical comparisons were conducted. The primary analysis was conducted as a single-arm analysis for each regimen.

The study experienced enrollment difficulties due to the small number of HCV treatment failures from select SOF-based regimens who would be eligible for this study, and closed to accrual prematurely. The participants enrolled remained on study until completion of follow-up.

Eligibility criteria: Inclusion Criteria:

* Willing and able to provide written informed consent
* Documentation of non-cirrhotic or cirrhotic status
* HIV-1 infection
* HIV antiretroviral treatment status (ART), CD4+ T-cell (CD4) count and HIV-1 RNA as follows: (1) not on ART with CD4 count \>500 cells/mm\^3 within 42 days of study entry, (2) elite controller not on ART with CD4 \>200 cells/mm\^3 within 42 days of study entry and HIV-1 RNA \<500 copies/mL on all measurements within 48 weeks prior to study entry, (3) on a stable protocol-approved ART with CD4 count \>200 cells/mm\^3 and HIV-1 RNA \<50 copies/mL within 42 days of study entry
* HCV GT-1 within 12 months prior to study entry
* Prior virologic treatment failure with SOF-containing regimen (SOF/RBV, SOF/PEG/RBV, and SOF/SIM)
* Body mass index (BMI) ≥18 kg/m\^2 within 42 days prior to study entry
* Certain laboratory values obtained within 42 days prior to study entry
* Hemoglobin ≥12.0 g/dL for male, ≥11.0 g/dL for female participants
* Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase (ALT) (SGOT) \<10 x ULN
* For female participants of reproductive potential, a negative serum pregnancy test with a sensitivity of at least 25 mIU/mL performed at screening and within 48 hours prior to study entry
* Agreement to use at least two reliable forms of contraceptive simultaneously while receiving study treatment and for 6 months afterward
* Intention to comply with the dosing instructions and study schedule of assessments

Exclusion Criteria:

* Receipt of any investigational drug or device within 60 days prior to study entry
* Prior exposure to a DAA other than SOF and SIM
* Chronic liver disease of a non-HCV etiology
* Presence of active or acute AIDS-defining opportunistic infections within 42 days prior to study entry
* Active, serious infection (other than HIV-1 or HCV) requiring parenteral antibiotics, antivirals, or antifungals within 42 days prior to study entry
* Hepatitis B virus (HBV) infection (defined as HBsAg positive) within 42 days prior to study entry
* History of clinically significant hemoglobinopathy
* Chronic current use of systemically administered immunosuppressive agents
* History of solid organ transplantation
* Current or prior history of clinical hepatic decompensation
* History of a gastrointestinal disorder (or postoperative condition) that could interfere with the absorption of the study drug
* History of significant or symptomatic pulmonary disease, cardiac disease, or porphyria that in the opinion of the investigator would interfere with the study
* History of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
* Active drug or alcohol use or dependence
* Use of any prohibited concomitant medications per the LDV/SOF product labeling, within 42 days prior to study entry
* Known hypersensitivity to RBV, SOF, LDV, their metabolites, or formulation excipients or any other contraindication to the use of RBV, SOF or LDV
* Currently receiving zidovudine (ZDV), didanosine (ddI), stavudine (d4T) or tipranavir
* Acute HIV infection defined as the phase immediately following infection during which anti-HIV antibodies are undetectable
* Known hepatocellular carcinoma
* Breastfeeding or pregnancy
* A male participant with a pregnant female partner
* Receipt of colony stimulating agents, including but not limited to erythropoietin, within 42 days prior to study entry

Primary outcomes:
measure: Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12)
timeFrame: At 12 weeks after treatment discontinuation (i.e., at 24 weeks after study entry in Arm A and at 36 weeks after study entry in Arm B).
measure: Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment
timeFrame: From study treatment initiation to 30 days after study treatment discontinuation. Duration of treatment was 12 weeks in Arm A and 24 weeks in Arm B.
Secondary outcomes:
measure: Percentage of Participants With Protocol-specified Renal Events
timeFrame: From study entry to study completion (Week 36 in Arm A, Week 48 in Arm B)
measure: Percentage of Participants With Sustained Virologic Response at 4 Weeks After Treatment Discontinuation (SVR4)
timeFrame: At 4 weeks after treatment discontinuation (i.e., at 16 weeks after study entry in Arm A and at 28 weeks after study entry in Arm B).
measure: Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24)
timeFrame: At 24 weeks after treatment discontinuation (i.e., at 36 weeks after study entry in Arm A and at 48 weeks after study entry in Arm B).
measure: Number of Participants With Unquantifiable HCV RNA
timeFrame: Entry (Week 0); at 1, 4, 8, 12 (and 16, 20, 24 in Arm B) weeks after study entry
measure: Number of Participants With HIV-1 RNA >50 Copies/mL
timeFrame: Entry (Week 0); at 4, 12 (and 24 in Arm B) weeks after study entry, and at 4 weeks after treatment discontinuation
measure: CD4+ T-cell (CD4) Count Change From Baseline
timeFrame: Entry and at 12 (and 24 in Arm B) weeks after study entry
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Ucsf Aids Crs (801)
state: California
city: New York
country: United States
facility: 7804 Weill Cornell Chelsea CRS
state: New York
Study officials:
affiliation: University of California, San Francisco HIV/AIDS CRS
name: Annie Luetkemeyer, MD
role: STUDY_CHAIR
affiliation: University of Colorado, Denver
name: Jennifer J. Kiser, PharmD
role: STUDY_CHAIR
References:
citation: Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS Jr; RESCUE and ACTG A5348 study investigators. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naive patients: Findings from two randomized trials. Liver Int. 2018 Jun;38(6):1010-1021. doi: 10.1111/liv.13616. Epub 2017 Dec 5.